News
Novo Nordisk, FDA and fatty liver disease
Digest more
The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.
Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...
GlobalData on MSN1d
Madrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...
Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...
Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...
Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback